Leearne (CEO) has often referred to 'fast to market' options for BD1 to get to commercialization adding SubB2m to existing tests to dramatically improve the specificity (reduce the number of false positives) of tests that they outlined in the announcement. Just another good step for the business in proving they have amazing technology and the people to bring it to fruition. We seem to be on a winner with BD1.
Leearne (CEO) has often referred to 'fast to market' options for...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.0¢ |
Change
-0.010(1.67%) |
Mkt cap ! $65.06M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 60.0¢ | 59.0¢ | $17.47K | 29.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 41547 | 58.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 13799 | 4 |
View Market Depth
| Last trade - 15.51pm 26/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |